Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      • Home
      • Farhat Nasim

      Articles By : Farhat Nasim

      Medical Devices Draft Bill 2019: Niti Ayog holds meeting with affected patients, stakeholders

      Medical Devices Draft Bill 2019: Niti Ayog holds meeting with affected patients, stakeholders

      Farhat Nasim21 Dec 2019 2:52 PM IST
      New Delhi: The Government's think tank- Niti Ayog has stepped up in curing the malaise due to faulty medical devices as it has gone ahead and met the...
      Lupin gets USFDA nod for generic version of Diprolene Ointment

      Lupin gets USFDA nod for generic version of Diprolene Ointment

      Farhat Nasim21 Dec 2019 9:40 AM IST
      Betamethasone Dipropionate Ointment USP (Augmented), 0.05% is a generic version of Diprolene Ointment and will be manufactured at the company’s...
      Suven Life Sciences Pashamylaram facility gets EIR from USFDA

      Suven Life Sciences Pashamylaram facility gets EIR from USFDA

      Farhat Nasim21 Dec 2019 9:30 AM IST
      Hyderabad: Suven Life Sciences Limited recently announced that the company has undergone the US health regulator's renewal inspection at their...
      NPPA fixes retail price of 44 combo drugs including Metformin, Vildagliptin, Paracetamol; Details

      NPPA fixes retail price of 44 combo drugs including Metformin, Vildagliptin, Paracetamol; Details

      Farhat Nasim20 Dec 2019 11:55 AM IST
      New Delhi: Through a recent notification, the apex drug price regulatory agency, the National Pharmaceutical Pricing Authority (NPPA) has fixed the...
      NPPA show-cause notices to Sun Pharma, Glenmark, Abbott, Lupin for self-exemption from price cap for anti-diabetic drugs

      NPPA show-cause notices to Sun Pharma, Glenmark, Abbott, Lupin for self-exemption from price cap for anti-diabetic drugs

      Farhat Nasim19 Dec 2019 2:26 PM IST
      New Delhi: The National Pharmaceutical Pricing Authority (NPPA) has called for action and issued show-cause notices to drug giants including Sun...
      Discrepancies in documents submitted by Meril Life Science for exempting MeRes100 from price cap; NPPA stalls decision

      Discrepancies in documents submitted by Meril Life Science for exempting MeRes100 from price cap; NPPA stalls decision

      Farhat Nasim18 Dec 2019 2:55 PM IST
      New Delhi: In a blow to Gujarat-based stent maker, Meril Life Sciences, the apex price regulator, National Pharmaceutical Pricing Authority (NPPA) has...
      Sanofi Allegra shows positive results in phase 3 study for allergic rhinitis

      Sanofi Allegra shows positive results in phase 3 study for allergic rhinitis

      Farhat Nasim18 Dec 2019 9:15 AM IST
      "The study demonstrated that Allegra/Telfast 180mg significantly decreased pollution- exacerbated AR symptoms by 21% (p=0.0148) in adult allergic...
      Medical Device Park: DoP to provide financial assistance to tune of Rs 25 crore; says MOS Health

      Medical Device Park: DoP to provide financial assistance to tune of Rs 25 crore; says MOS Health

      Farhat Nasim17 Dec 2019 2:47 PM IST
      Choubey further mentioned that DoP has received four proposals under this sub-scheme from Andhra Pradesh Medtech Zone Ltd. (AMTZ), Andhra Pradesh;...
      Issue of Corruption in CDSCO raised in Parliament; Details

      Issue of Corruption in CDSCO raised in Parliament; Details

      Farhat Nasim16 Dec 2019 12:56 PM IST
      New Delhi: The sensitive issue of corruption plaguing every sector including the nodal drug regulatory body, Central Drugs Control Organisation...
      CDSCO to set up Public Relations Offices at all Zonal, Sub-Zonal Offices for regulator guidance

      CDSCO to set up Public Relations Offices at all Zonal, Sub-Zonal Offices for regulator guidance

      Farhat Nasim15 Dec 2019 1:42 PM IST
      New Delhi: In order to make regulatory guidance more accessible across the country, the nodal drug regulator, Central Drugs Standard Control...
      Pfizer gets USFDA nod for Xeljanz XR Extended-Release Tablets to treat Ulcerative Colitis

      Pfizer gets USFDA nod for Xeljanz XR Extended-Release Tablets to treat Ulcerative Colitis

      Farhat Nasim15 Dec 2019 10:00 AM IST
      New Delhi: Pfizer Inc. recently announced that the U.S. Food and Drug Administration (FDA) has approved XELJANZ XR (tofacitinib) extended-release 11...
      Sanofi to reduce investment in Onduo, USD 500 million joint venture with Verily

      Sanofi to reduce investment in Onduo, USD 500 million joint venture with Verily

      Farhat Nasim14 Dec 2019 1:55 PM IST
      However, after several years of partnership, the two parties do not seem to align well as Sanofi recently withdrew from the Joint Venture, Onduo...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok